Prostate Cancer - Results from #60

Multi-gene risk-score for prediction of clinical outcomes in treatment-naïve metastatic castrate resistant prostate cancer. March 6, 2025

Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States. March 6, 2025

Intact Glycopeptide Analysis of Human Prostate Tissue Reveals Site-Specific Heterogeneity of Protein Glycosylation in Prostate Cancer. March 6, 2025

5-hydroxymethylcytosine sequencing of plasma cell-free DNA identifies epigenomic features in prostate cancer patients receiving androgen deprivation therapies. March 6, 2025

SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences. March 5, 2025

Cancer mortality predictions for 2025 in Latin America with focus on prostate cancer. March 5, 2025

Perceptions and Use of Germline Genetic Testing Among Patients With Prostate Cancer. March 5, 2025

Does Size Matter? A Retrospective Study Analysing the Size of PI-RADS 4 Lesions and Its Associated Prostate Cancer Positivity with Transperineal Prostate Biopsy. March 5, 2025

A Polygenic Risk Score for Late Bladder Toxicity Following Radiotherapy for Non-Metastatic Prostate Cancer. March 5, 2025

Prostate Specific Antigen Density and Clinically-Significant Prostate Cancer: The Influence of Prostatic Volume. March 5, 2025

Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC. March 5, 2025

Increasing Prostate Cancer Education and Screening for Black Men in Southeastern Michigan: Your Prostate, Your Health. March 4, 2025

Locations of metastases in and oncological outcomes of patients with metastatic castration-sensitive prostate cancer: Real-world data from a multicenter study. March 4, 2025

Incidence of Significant Prostate Cancer in the Follow-Up of Patients With Suspicious Lesion on MRI and Negative Targeted and systematic Biopsies. March 4, 2025

Cardiovascular Risks and Survival with Abiraterone vs Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer in Germany: AVENGER Study. March 4, 2025

A retrospective analysis of tissue, liquid, and germline testing in Hispanic and non-Hispanic men with advanced hormone-sensitive prostate cancer. March 4, 2025

Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy. March 3, 2025

Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study. March 3, 2025

AI-powered prostate cancer detection: a multi-centre, multi-scanner validation study. March 3, 2025

The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy. March 3, 2025

Page 4 of 1465